When it comes to driving innovation in the healthcare industry, Lyse Santoro puts her faith in this quote and believes in creating opportunities. Backed by 17 years of experience in strategic and operational top management positions in diagnostic and pharmaceutical companies and 10 years of experience in biotech companies, Lyse has unlocked an opportunity to redefine the realm of emergency cardiac diagnosis. As the CEO of Magnisense, Lyse leads her team to provide immediate and efficient bedside diagnostic tests to prevent medical emergencies, particularly for cardiovascular diseases. Governed by a mission to help build the medicine of tomorrow by improving emergency diagnosis, Magnisense emphasizes early diagnosis of myocardial infarction to quickly guide and initiate the right treatment.
Lyse points out that ECG profiles are not enough in some cases and fail to detect heart-failure in emergencies. That why the healthcare authorities strongly recommend to quantify blood cardiac biomarkers to be able to confirm the diagnosis. This quantification of biomarkers are usually performed in the central lab of hospitals, by using big automates which makes the diagnosis confirmation a rigid, time-consuming process, taking hours to discern any seizures and complicating the situation. “Magnisense aims to pave the way for the future of emergency medicine by leveraging flexible, preventive, connected, and proximity medicine emergency care in cardiovascular infarctions,” says Lyse. The company’s flagship product MiAG®, a best-in-class mobile testing device, draws quantitative and highly subjective quantification of cardiac biomolecules directly from blood, from anywhere—at home, hospitals, ambulances, planes, or trains—in just 15 minutes.
Powered by MiAtek® technologies that are based on the use of magnetic nanoparticles, MiAG® is the first mobile IAG in the world that is precisely adaptable to emergencies. MiAG® can do at least three tests in parallel within 15 minutes, and its user-friendly interface, zero maintenance, auto calibration capabilities and intellective digital corrode screen help the clients to do their tests step-by-step.
Magnisense aims to pave the way for the future of emergency medicine by leveraging flexible, preventive, connected, and proximity medicine emergency care in cardiovascular infarctions
“Upon swiftly detecting cardiovascular impairments in emergencies, caregivers will be able to call the right hospitals, prepare the operation room, or give emergency medication as per the needs of a patient, quickly and effectively. With MiAG®, the clients can confirm the diagnosis and initiate the therapeutic methods for the patient in no time,” adds Lyse. At the core, MiAG® envisions accomplishing three goals: save lives of patients; allow the hospitals or clinics to be better organized by setting up innovative pathways within the hospitals; and contribute to decreasing the costs associated with the management of these diseases.
Magnisense stands out in the market with its unique technology and strong worldwide patent protection. The quality and accuracy of results provided by MiAG® is perfectly identical with the results given by the hospitals. The company’s young, energetic, and experienced team reflects a real start-up spirit and professionalism, which is indeed a winning strategy. Magnisense is proud of its French roots and all the operations of the company—including production and R&D—are performed in France itself.
In an instance, Magnisense was able to prevent one of its clients, a small clinic in Switzerland, from making an inaccurate diagnosis. The MiAG® test helped the physician to identify a nearly acute heart failure in one of his patients, who came with lung troubles and was diagnosed initially with bronchitis. Upon detection with heart failure, the patient was given immediate emergency care, which helped save his life. MiAG® helped the physician to understand the gravity of the situation, save his patient and uphold his Hippocratic Oath, substantially boosting the clinics’ reputation in town.
Magnisense has been passionate in exceeding the expectations of their clients and the stakeholders for the past decade and will continue to do the same in the future by investing an additional €5 million for market expansion. The company already obtained the CE marking for its tests and is all set to launch more tests in the coming years. Besides expansion in Europe, Magnisense plans to miniaturize its product for the home testing market, attempting to shift the paradigm of emergency care directly to the patients.